Slide 1: Q1 2024 Results
Q1 2024 Results Conference call and webcast for investors and analysts 25 April 2024
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the ‘safe harbour’ provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements wit
Slide 3: Conference call agenda
Q1 2024 Results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Dave Fredrickson Susan Galbraith EVP, Oncology Business EVP, Oncology R&D BioPharmaceuticals Ruud Dobber Sharon Barr EVP, BioPharmaceutic
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 5: Strong delivery in Q1 2024
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Strong delivery in Q1 2024 Total Revenue growth Core EPS growth fueled by global Product Sales despite substantial decrease in Other Operating Income1 +19% +13% $12,679 m $2.06 $10,879 m $1.92 Q1 2023
Slide 6: Growth across therapy areas and geographies
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Growth across therapy areas and geographies Total Revenue, $m Total Revenue, $m +26% +23% +16% +17% (34%) 5,108 3,060 1,886 2,096 232 Oncology CVRM R&I Rare disease V&I Double-digit growth across thera
Slide 7: Q1 2024 pipeline events unlock significant growth potential
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Q1 2024 pipeline events unlock significant growth potential Unprecedented Phase III results Transformative new approvals Phase III ADRIATIC trial Tagrisso + CTx Enhertu Ultomiris • Imfinzi potentially
Slide 8: Financial Results
Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER
Slide 9: Q1 2024 – Reported profit and loss
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Q1 2024 – Reported profit and loss Q1 2024 CER change % Total $m % Revenue - Product Sales 12,177 18 96 - Alliance Revenue 457 59 4 - Collaboration Revenue 45 66 - Total Revenue 12,679 19 100 Product S
Slide 10: Q1 2024 – Core profit and loss
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Q1 2024 – Core profit and loss Q1 2024 CER change % Total $m % Revenue - Product Sales 12,177 18 96 - Alliance Revenue 457 59 4 - Collaboration Revenue 45 66 - Total Revenue 12,679 19 100 Product Sales
Slide 11: Net debt and FY guidance
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Net debt and FY guidance Reiterating FY 2024 guidance Net debt bridge FY 2024 guidance reiterated (CER) $bn Total Revenue • Low double-digit to low teens percentage increase Core EPS • Low double-digit
Slide 12: Oncology
Oncology Dave Fredrickson ONCOLOGY BUSINESS Susan Galbraith ONCOLOGY R&D
Slide 13: Oncology – Q1 2024
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – Q1 2024 Total Revenue +26% with strong double-digit growth across all regions Oncology Q1 2024: key dynamics Q1 2024 $5.1bn, +26% 6,000 • Tagrisso +15%, continued ADAURA and FLAURA demand, s
Slide 14: Oncology – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology – R&D highlights Fusion Pharmaceuticals acquisition expands next-gen Radioconjugate capabilities FPI-2265 in Prostate cancer 30-50% of patients PSMA-Actinium RC with potential post-Pluvicto an
Slide 15: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Sharon Barr BIOPHARMACEUTICALS R&D
Slide 16: BioPharmaceuticals – Q1 2024
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – Q1 2024 Total Revenue $5.2bn, +16% – demand growth, accelerating new launch momentum CVRM R&I Q1 2024 $3.1bn, +23% Q1 2024 $1.9bn, +17% • >18k unique prescribers1 • 65k TRx in 1Q24
Slide 17: BioPharmaceuticals – R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals – R&D highlights Exploratory endpoints support confidence in upcoming ATTR-CM opportunity Phase III NEURO-TTRansform Cardiomyopathic exploratory endpoints1 CARDIO-TTRansform largest
Slide 18: Rare Disease
Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION
Slide 19: Rare Disease – Q1 2024
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease – Q1 2024 Total Revenue +16% in Q1 2024 driven by neurology Rare Disease Q1 2024: key dynamics Q1 2024 $2.1bn, +16% 2,500 Sustainable, durable growth of C5 Franchise 2,000 • Ultomiris +34%
Slide 20: Rare Disease – R&D
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease – R&D Blockbuster opportunity with proposed Amolyt Pharma acquisition eneboparatide | Phase IIa hypoparathyroidism Potential best-in-class therapy with differentiated Serum calcium (mean A
Slide 21: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 22: Increasing momentum of high-value pipeline
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Increasing momentum of high-value pipeline Significant pipeline catalysts over the Phase III trial initiations since FY2023 remainder of 2024 TROPION-Lung10 Dato-DXd ± TROPION-Lung141 Dato-DXd ± Nonsq
Slide 23: Q&A Session
Q&A Session Pascal Soriot Aradhana Sarin Marc Dunoyer E X E C U TIVE D I REC TOR & E X E C U TIVE D I REC TOR & C H I E F E X E C U TIVE O F F I C E R, C H I E F E X E C U TIVE O F F I C E R C H I E F F I N A N C I AL O F F I C ER ALEXION Susan Galbraith Dave Fredrickson Sharon Barr E X E C U TIVE V
Slide 24: Appendix & Glossary
Appendix & Glossary • Glossary • ESG – summary of sustainability progress • Oncology tumour maps • Emerging Markets performance • Key medicines performance by therapy area
Slide 25: Glossary – abbreviations
G L O S S A R Y | Q1 2024 Glossary – abbreviations 1L = First-line or Front-line hMPV/RSV = Human metapneumovirus/respiratory syncytial virus 2L = Second-line HPP = Hypophosphatasia 6MWT = 6-minute walk test HtN = Hypertension ADsCa = Albumin-adjusted serum calcium IgAN = Immunoglobulin A Nephropath
Slide 26: 2023 Sustainability highlights
A P P E N D I X | Sustainability update 2023 Sustainability highlights Progress on our overall Access to Healthcare Environmental Protection Ethics and Transparency strategy includes: 15 127,384 67.6% 50.1% public and private sector organisations healthcare workers and others trained1 reduction in S
Slide 27: AstraZeneca in Lung Cancer
A P P E N D I X | Oncology tumour maps AstraZeneca in Lung Cancer Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030 resectable Stg. I-III unresectable Stg. I-II Stg. III 1L metastatic 2L+ Leading the future of Est. epi (G7) ~200K ~30K ~70K ~350K ~290K lung cancer trea
Slide 28: AstraZeneca in Breast Cancer
A P P E N D I X | Oncology tumour maps AstraZeneca in Breast Cancer Ambition to eliminate breast cancer as a cause of death established SoC Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7) 540k 125k 90k 65k 55k Enhertu ± THP NST residual disease HER2-posit
Slide 29: AstraZeneca in Breast Cancer
A P P E N D I X | Oncology tumour maps AstraZeneca in Breast Cancer Ambition to eliminate breast cancer as a cause of death Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7) 405k 80k 65k 55k 50k Current SoC drives Camizestrant to replace ET PIK3CA/AKT1/PTEN al
Slide 30: Oncology
A P P E N D I X | Total Revenue Performance Oncology Tagrisso Lynparza 15% growth at CER to $1,595m in Q1 2024 11% growth at CER to $705m in Q1 2024 1,800 1,200 1,600 1,000 1,400 1,200 800 Total Revenue ($m) Total Revenue ($m) 1,000 600 800 600 400 400 200 200 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3
Slide 31: Oncology
A P P E N D I X | Total Revenue Performance Oncology Imfinzi Imjudo 33% growth at CER to $1,113m in Q1 2024 70% growth at CER to $62m in Q1 2024 1,200 70 60 1,000 50 800 Total Revenue ($m) Total Revenue ($m) 40 600 30 400 20 200 10 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2022 2023
Slide 32: Oncology
A P P E N D I X | Total Revenue Performance Oncology Calquence Enhertu 35% growth at CER to $718m in Q1 2024 79% growth at CER to $461m in Q1 2024 800 500 700 450 400 600 350 Total Revenue ($m) 500 Total Revenue ($m) 300 400 250 300 200 150 200 100 100 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q
Slide 33: BioPharmaceuticals: Cardiovascular, Renal & Metabolism
A P P E N D I X | Total Revenue Performance BioPharmaceuticals: Cardiovascular, Renal & Metabolism Farxiga Brilinta Lokelma 45% growth at CER to $1,892m in Q1 2024 1% decrease at CER to $323m in Q1 2024 19% growth at CER to $114m in Q1 2024 2,000 400 120 1,800 350 100 1,600 300 1,400 80 Total Revenu
Slide 34: BioPharmaceuticals: Respiratory & Immunology
A P P E N D I X | Total Revenue Performance BioPharmaceuticals: Respiratory & Immunology Fasenra Breztri Tezspire 6% growth at CER to $358m in Q1 2024 54% growth at CER to $219m in Q1 2024 >2x growth at CER to $120m in Q1 2024 450 250 140 400 120 350 200 100 300 Total Revenue ($m) Total Revenue ($m)
Slide 35: BioPharmaceuticals: Respiratory & Immunology
A P P E N D I X | Total Revenue Performance BioPharmaceuticals: Respiratory & Immunology Symbicort Pulmicort 14% growth at CER to $769m in Q1 2024 5% growth at CER to $224m in Q1 2024 900 250 800 700 200 600 Total Revenue ($m) Total Revenue ($m) 150 500 400 100 300 200 50 100 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q
Slide 36: Rare Disease
A P P E N D I X | Total Revenue Performance Rare Disease Ultomiris Soliris Strensiq 34% growth at CER to $859m in Q1 2024 8% decrease at CER to $739m in Q1 2024 21% growth at CER to $313m in Q1 2024 1,000 1,200 350 900 300 1,000 800 700 250 800 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m